Custom Search

Monday, July 18, 2011

Factor Xa inhibitor for treatment of deep vein thrombosis in knee and hip replacement surgery

New drug first oral drug to reduce risk of formation of blood clot after hip / knee replacement surgery.

Patients undergoing keen and hip surgeries are more susceptible for developing deep vein thrombosis and then to pulmonary embolism which may develop in to life threatening stroke, because of the surgical procedures the patients undergoing hip and knee replacement surgeries are more susceptible to develop thrombosis. Thromboembolism poses great risk to patient towards stroke, therefore after such surgeries patients are required to be treated with anticoagulant therapies.

US FDA approved first drug which is a direct inhibitor of factor Xa , the molecule name of the molecule is Rivaroxaban and its brand name is Xarelto it is marketed in united states by Janssen Pharmaceuticals.

The drug Xarelto (rivaroxaban) is a first oraly taken inhibitor of factor xa, ( factor X a is an enzyme in the blood coagulation path way it act up on prothrombin and convert prothrombin to thrombin also see here.
Drug Xarelto is a once a day pill the pill is recommended for 12 days for patients under going knee replacement and for patient it is given for 35 days.



Other FDA approved drugs which are used as anticoagulants are as follows
Coumadin (warfarin), Heparin, Lovenox (enoxaparin), generic versions of enoxaparin, Arixtra (fondaparinux), Fragmin (dalteparin) only for hip replacement sergery.
Side effects observed with Xarelto is excessive bleeding, which is one of the common side effect associated with all anticoagulant drugs.

US FDA approves Pradaxa capsules (dabigatran etexilate) to prevent stroke in people with atrial fibrillation

Bypass surgery on brain artery now can be done without halting blood flow

A product to treat congenital deficiency of blood clotting factor XIII approved by US FDA

Also see

What is blow fill seal technology in sterile dosage form


Aspects of Validation of Aseptic Process and Sterilisation , Sterilization of Equipment, Containers, and Closures

What is pharmaceutical product information manual (Pharmaceutical product dossier) for registration of  pharmaceutical product to foreign countries

US FDA limits dosage of acetaminophen to 325 mg per unit dosage form,Requires boxed warning on lables

What is an Isolator in pharmaceutical manufacturing

What is a Laminar Air Flow Cabinet?

21 cfr part 11 FDA guidelines .

Media Fill Run To Ensure Sterility In Sterile Dosage Forms

What is HEPA filter?

 Jobs in Pharma company Find best Pharma sales job

No comments:

Posted by: Martin

How to sucessfuly activate and receive our articles on pharmaceuticals by E-Mail

Dear readers if you wish to receive our articles on pharmaceutical automatically into your email Inbox , as and when we write a new article over this website, then follow these 3 simple steps.


1.You should write your Email ID in the box provided and push the subscribe butten


2.Enter the text code that we show you in a small new browser window after you enter your email ID.

3.Log in to your email and Cheke our verification email sent by "FEEDBURNER" , there you should verify the link we send you by email.




Enter your email address get our articles by email whenever this website is updated





Delivered by FeedBurner



Join the list of our readers from Universities ,Research and Development centers Pharmaceutical Companies from all over the world.











Pharma Research Regulatory Guidelines Website
Texas Dallas, TX 75211 US
Email: editor@pharmacistspharmajournal.org Website: http://pharmacistspharmajournal.org/
Copyright © 2008-2015 all rights reserve www.pharmacistspharmajournal.org